Skip to main content

Table 2 Subgroup analysis of circulating FABP4, nesfatin-1, and OC levels in patients with GDM

From: Circulating FABP4, nesfatin-1, and osteocalcin concentrations in women with gestational diabetes mellitus: a meta-analysis

Subgroups

N

Test of association

Test of heterogeneity

SMD (95% CI)

z

P

I2(%)

P

FABP4

 Ethnicity

  Asian

15

3.45 (2.65 to 4.25)

8.47

< 0.01

96.40

< 0.01

  Australoid

1

1.52 (0.14 to 2.89)

2.16

0.03

96.50

< 0.01

  Caucasian

3

0.71 (0.34 to 1.07)

3.75

< 0.01

NA

NA

  Combined

19

2.99 (2.28 to 3.69)

8.32

< 0.01

96.90

< 0.01

 Age(mean,years)

   < 30

11

3.49 (2.50 to 4.47)

6.94

< 0.01

96.50

< 0.01

   ≥ 30

8

2.30 (1.37 to 3.23)

4.84

< 0.01

96.70

< 0.01

  Combined

19

2.99 (2.28 to 3.69)

8.32

< 0.01

96.90

< 0.01

 BMI(mean,kg/m2)

   < 25

8

2.37 (1.37 to 3.37)

4.65

< 0.01

96.40

< 0.01

   ≥ 25

11

3.43 (2.51 to 4.34)

7.33

< 0.01

96.80

< 0.01

  Combined

19

2.99 (2.28 to 3.69)

8.32

< 0.01

96.90

< 0.01

 Study type

  Case-control

18

3.12 (2.40 to 3.84)

8.51

< 0.01

96.70

< 0.01

  Cohort

1

0.71 (0.34 to 1.07)

3.75

< 0.01

NA

NA

  Combined

19

2.99 (2.28 to 3.69)

8.32

< 0.01

96.90

< 0.01

 ELISA kits

  R&D Systems

11

3.73 (2.64 to 4.83)

6.68

< 0.01

35.60

0.26

  BioVendor

2

1.39 (−0.62 to 3.40)

1.35

0.18

40.50

0.38

  other kits

6

2.25 (1.27 to 3.23)

4.51

< 0.01

25.30

0.15

  Combined

19

2.99 (2.28 to 3.69)

8.32

< 0.01

96.90

< 0.01

 Diagnostic criteria

  IADPSG

6

3.36 (2.03 to 4.68)

4.98

< 0.01

97.00

< 0.01

  C&C

1

2.41 (2.03 to 2.79)

12.40

< 0.01

NA

NA

  ADIPS

2

0.54 (0.20 to 0.87)

3.15

< 0.01

37.20

0.21

  ADA

5

2.79 (1.78 to 3.80)

5.40

< 0.01

95.00

< 0.01

  NDDG

2

5.37 (4.48 to 6.26)

11.86

< 0.01

36.80

0.21

  ACOG

3

2.99 (0.12 to 5.86)

2.04

0.04

97.30

< 0.01

  Combined

19

2.99 (2.28 to 3.69)

8.32

< 0.01

96.90

< 0.01

 Measurement trimester

  Second

10

3.40 (2.43 to 4.38)

6.88

< 0.01

97.10

< 0.01

  Third

9

2.53 (1.46 to 3.60)

4.64

< 0.01

96.80

< 0.01

  Combined

19

2.99 (2.28 to 3.69)

8.32

< 0.01

96.90

< 0.01

Nesfatin-1

 Ethnicity

  Asian

10

−0.08 (−0.64 to 0.47)

0.30

0.76

92.90

< 0.01

  Caucasian

1

−0.41 (− 0.68 to − 0.14)

2.98

< 0.01

NA

NA

  Combined

11

−0.11 (− 0.61 to 0.38)

0.45

0.65

93.00

< 0.01

 Age(mean,years)

   < 30

7

−0.33 (− 0.98 to 0.32)

1.00

0.32

92.70

< 0.01

   ≥ 30

4

0.25 (−0.50 to 1.00)

0.65

0.52

92.50

< 0.01

  Combined

11

−0.11 (− 0.61 to 0.38)

0.45

0.65

93.00

< 0.01

 BMI(mean,kg/m2)

   < 25

5

−0.03 (− 0.92 to 0.87)

0.06

0.96

94.60

< 0.01

   ≥ 25

5

−0.44 (− 0.63 to − 0.25)

4.60

< 0.01

0

0.66

  Combined

10

−0.23 (− 0.72 to 0.26)

0.91

0.36

91.30

< 0.01

 ELISA kits

  Uscn Life Science Inc.

2

−0.38 (− 0.83 to 0.06)

1.66

0.10

39.30

0.19

  R&D Systems

3

0.88 (0.68 to 1.09)

8.47

< 0.01

0

0.62

  other kits

6

−0.54 (−1.14 to 0.05)

1.79

0.07

40.30

0.25

  Combined

11

−0.11 (− 0.61 to 0.38)

0.45

0.65

93.00

< 0.01

 Diagnostic criteria

  ACOG

1

−0.15 (− 0.65 to 0.36)

0.56

0.57

NA

NA

  ADA

7

−0.13 (− 0.88 to 0.62)

0.34

0.74

94.40

< 0.01

  C&C

1

−0.61 (− 1.09 to − 0.12)

2.45

0.01

NA

NA

  IADPSG

1

0.73 (0.32 to 1.13)

3.51

< 0.01

NA

NA

  WHO

1

−0.41 (−0.68 to − 0.14)

2.98

< 0.01

NA

NA

  Combined

11

−0.11(− 0.61 to 0.38)

0.45

0.65

93.00

< 0.01

 Measurement trimester

  Second

7

−0.35 (− 0.97 to 0.26)

1.13

0.26

93.00

< 0.01

  Third

4

0.35 (−0.26 to 0.96)

1.14

0.26

85.00

< 0.01

  Combined

11

−0.11 (− 0.61 to 0.38)

0.45

0.65

93.00

< 0.01

OC

 Asian

9

0.83 (0.42 to 1.24)

3.98

< 0.01

88.20

< 0.01

 Austrian

1

0.61 (0.13 to 1.09)

2.49

0.01

NA

NA

 Australoid

2

0.04 (−1.10 to 1.18)

0.07

0.95

94.80

< 0.01

 Combined

12

0.68 (0.31 to 1.05)

3.64

< 0.01

89.40

< 0.01

 Age(mean,years)

   < 30

7

0.98 (0.42 to 1.55)

3.43

< 0.01

90.80

< 0.01

   ≥ 30

5

0.32 (−0.12 to 0.76)

1.44

0.15

85.00

< 0.01

  Combined

12

0.68 (0.31 to 1.05)

3.64

< 0.01

89.40

< 0.01

 BMI(mean,kg/m2)

   < 25

4

0.55 (0.37 to 0.73)

5.94

< 0.01

0

0.86

   ≥ 25

8

0.80 (0.19 to 1.40)

2.60

< 0.01

93.20

< 0.01

  Combined

12

0.68 (0.31 to 1.05)

3.64

< 0.01

89.40

< 0.01

 Measurement type

  ELISA

6

1.04 (0.33 to 1.75)

2.86

< 0.01

92.50

0

  IRMA

1

−0.54 (− 0.90 to − 0.18)

2.90

< 0.01

NA

NA

  ECLIA

5

0.60 (0.44 to 0.76)

7.29

< 0.01

0

0.91

  Combined

12

0.68 (0.31 to 1.05)

3.64

< 0.01

89.40

< 0.01

 Different forms of OC

  ucOC

4

0.50 (0.29 to 0.71)

4.75

< 0.01

0

0.41

  tOC

8

0.82 (0.27 to 1.37)

2.91

< 0.01

93.00

< 0.01

  Combined

12

0.68 (0.31 to 1.05)

3.64

< 0.01

89.40

< 0.01

 Measurement trimester

  Second

4

0.64 (0.46 to 0.82)

6.91

< 0.01

0

0.99

  Third

8

0.75 (0.17 to 1.34)

2.51

< 0.01

93.00

< 0.01

  Combined

12

0.68 (0.31 to 1.05)

3.64

< 0.01

89.40

< 0.01

  1. N Number of cases, SMD Standardized mean difference, BMI Body mass index, ELASA Enzyme linked immunosorbent assay, IRMA Immunoradiometric assay, ECLIA Electrochemiluminescence immunoassay, NA Not available